Breast cancer - is the No.3 Killer in Hong Kong
| Breast cancer is the THIRD most deadly cancer among women in Hong Kong, second only to lung cancer and colorectal cancer. | |||
| In 2018, a total of 753 women died of breast cancer, accounting for 12.4% of female cancer deaths. | |||
| Breast cancer also happens occasionally in men. | |||
| ccording to the latest 2020 study, it is estimated that more than 5 million people in China carry BRCA disease-causing gene mutations. | |||
| In Asians, the risk of a cancer-causing mutation in the BRCA gene represent as below: | |||
|
|||
|
|||
|
|||
Specifically designed for Asians - common Asian-specific gene mutations
| Using next-generation sequencing (NGS) and the most advanced technology to detect any genetic mutations, including gene rearrangements and large deletions of BRCA1&2 genes, related to hereditary breast cancer and ovarian cancer. | |
| PANGENIA's Breast Cancer and Ovarian Cancer Screening (BRCA1&2) is designed for screening Asian genetic mutations, with a coverage up to 95%. |
PanBRCA™ Screening Test Features
Suitable For:
| Early onset breast cancer(<45years old) | |
| Bilateral or multiple primary breast cancers | |
| Male breast cancer at any age | |
| Breast and ovarian cancer in the same women | |
| 3 or more cases of breast cancer in the family | |
| 3 or more cases of breast, ovarian and/or pancreatic cancer in the family | |
| 3 or more cases of breast, uterine and/or thyroid cancer in the family | |
| Multiple close family members with breast and other cancers |
Test Specifications
| Test Code | Methodology | Specimen Requirements | Turnaround Time |
|---|---|---|---|
| OBS | NGS (Next Generation Sequencing) | 6ml blood in Lavender-top EDTA tube / 10 Buccal Swabs |
4-6 Weeks |
| OBF | NGS + Multiplex ligation-dependent probe amplification (MLPA) |